Company intelligence / Profile preview

Napp Pharmaceuticals

Cambridge, England, United Kingdomnapp.co.uk ↗

Ownership: Private
Employees: ~486
Development stage: Commercial

Overview

Napp Pharmaceuticals has an established commercial presence in the UK, offering products in pain management (including branded forms of oxycodone) and a broad range of therapies for chronic conditions such as diabetes, respiratory disease, cancer, arthritis, and gastrointestinal disorders[1][3][5]. The company introduced a prominent delivery technology (Continus®) for sustained drug release and has focused on supporting patient needs and the NHS with innovative medicines[1][4][5].

Therapeutic areas: OncologyPulmonologyRheumatologyNeurologyEndocrinologyGastroenterology
Modalities: Small moleculeBiologic
Industry: Pharma

Drug pipeline

3 assets

Adizem-XL

Unknown

2 more assets in the full pipeline.

Request access →

Beyond the preview

Go deeper on Napp Pharmaceuticals.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Napp Pharmaceuticals.

Explore the full profile